✦ LIBER ✦

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

✍ Scribed by Ma, W. W.; Messersmith, W. A.; Dy, G. K.; Weekes, C. D.; Whitworth, A.; Ren, C.; Maniar, M.; Wilhelm, F.; Eckhardt, S. G.; Adjei, A. A.

Book ID: 115455812
Publisher: American Association for Cancer Research
Year: 2012
Tongue: English
Weight: 440 KB
Volume: 18
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-11-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Study of GSK461364, a Specific a

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 988 KB

418 Phase I, clinical, pharmacokinetic a

418 Phase I, clinical, pharmacokinetic and schedule dependency study of the aurora kinase inhibitor AS703569 combined with gemcitabine in patients with solid tumors

✍ E. Raymond; J. Alexandre; T. Besse-Hammer; S. Faivre; B. Longerey; N. Rejeb; A. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A phase I schedule dependency study of t

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

✍ Raymond, E.; Alexandre, J.; Faivre, S.; Goldwasser, F.; Besse-Hammer, T.; Gianel 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 270 KB

431 POSTER A phase I first-in-human stud

431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors

✍ S. Blagden; D. Olmos; R. Sharma; J. Barriuso; H. Medani; M. Versola; S. Murray; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Phase I safety, pharmacokinetic, and pha

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

✍ Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 362 KB

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB